$100 Million awarded Since 1994 6,000 Satisfied Clients

Posted On November 1, 2024 Securities

Metagenomi (MGNI) Class Action Lawsuit 2024

NOTICE: If you suffered Metagenomi investment losses, contact the securities attorneys at Console & Associates to discuss your legal options. Submit a confidential Case Evaluation form here.

You may be eligible to join the Metagenomi class action lawsuit if you are an investor who purchased Metagenomi Inc. (NASDAQ: MGNI) common stock during the IPO between February 9-13, 2024? Have you suffered significant losses following the abrupt termination of Metagenomi’s collaboration with Moderna? You may be entitled to recover your losses through a securities class action lawsuit. The securities lawyers of Console & Associates, P.C. are investigating this matter and are ready to assist. Fill out our online form and a member of our team will be in touch.

What Happened at Metagenomi?

Metagenomi, a biotechnology company, conducted its Initial Public Offering (IPO) on February 13, 2024, selling 6.25 million shares at $15 per share. A key highlight in their IPO registration statement was the strategic collaboration with Moderna, which was positioned as a cornerstone for Metagenomi’s future growth and success.

However, less than three months after the IPO, Metagenomi announced on May 1, 2024, the termination of its collaboration agreement with Moderna. This unexpected news sent shockwaves through the investment community:

  • Stock Price Plummeted: The stock price fell dramatically from $7.04 to $6.17 on the day of the announcement.
  • Continued Decline: By the time of the class action filing, Metagenomi’s stock had plunged to approximately $2.15 per share, a stark contrast to the IPO price of $15.

The Allegations

The class action lawsuit alleges that Metagenomi made false and misleading statements in its IPO registration documents by failing to disclose material information:

  • Risk of Termination: The company allegedly knew, or should have known, that the partnership with Moderna was at imminent risk of termination.
  • Investor Deception: By withholding this critical information, Metagenomi misled investors about the true value and prospects of the company.

Your Rights as an Investor

If you purchased Metagenomi shares pursuant to or traceable to the IPO registration statement between February 9-13, 2024, you are part of the affected class and may be eligible to join a Metagenomi class action lawsuit. Under the Securities Act Sections 11 and 15, you have the right to seek compensation for:

  • Financial Losses: Recover the difference between the price you paid and the diminished value of your shares.
  • Damages for Misrepresentation: Hold Metagenomi accountable for the alleged securities fraud.

How to Join the Metagenomi Class Action

Time is of the essence. The longer you wait, the harder it may become to recover your losses:

  • Protect Your Investment: Ensure you are part of the Metagenomi class action lawsuit to maximize your potential recovery.
  • Hold Metagenomi Accountable: Your action can help enforce transparency and integrity in the market.

Don’t let your investment losses go unaddressed. Contact our securities lawyers for a free, no-obligation consultation to discuss your rights and options.

NOTICE: If you suffered Metagenomi investment losses, contact the securities attorneys at Console & Associates to discuss your legal options. Submit a confidential Case Evaluation form here.